Cargando…
Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata
OBJECTIVES: The present analyses report integrated results from BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) on the clinical benefits of baricitinib treatment on the basis of the amount of scalp hair regrowth through 52 weeks of treatment. METHODS: This post hoc analysis was conducted with da...
Autores principales: | Senna, Maryanne M., Kwon, Ohsang, Piraccini, Bianca M., Sinclair, Rodney, Ball, Susan, Ding, Yuxin, Chen, Yun-Fei, Dutronc, Yves, King, Brett |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689319/ https://www.ncbi.nlm.nih.gov/pubmed/37991697 http://dx.doi.org/10.1007/s13555-023-01063-2 |
Ejemplares similares
-
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
por: Kwon, Ohsang, et al.
Publicado: (2023) -
Development of the Scalp Hair Assessment PRO™ measure for alopecia areata
por: Wyrwich, K.W., et al.
Publicado: (2020) -
Treatment of severe alopecia areata with baricitinib
por: Olamiju, Brianna, et al.
Publicado: (2019) -
Baricitinib for the Treatment of Alopecia Areata
por: Freitas, Egídio, et al.
Publicado: (2023) -
Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab
por: Gruenstein, Diana, et al.
Publicado: (2020)